In January, after Eleven Biotherapeutics Inc. disclosed mixed phase III data in severe allergic conjunctivitis with the interleukin-1 (IL-1) signaling inhibitor EBI-005 (isunakinra) – which also proved a dud in the late-stage experiment for dry eye disease in May 2015 – the stock took a 77 percent hit and Wall Street retreated.